2067-80-3

Applied Filters:

Keyword:'2067-80-3'

Showing 1-1 of 1 result for "2067-80-3" within Papers

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Jennifer G Robinson et al.

JAMA, 311(18), 1870-1882 (2014-05-16)

In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin. Phase 3

Page 1 of 1